{"relation": [["", "Placebo to V950/IMX 0 mcg", "Placebo to V950/IMX 16 mcg", "V950 0.5 mcg/IMX 0 mcg", "V950 0.5 mcg/IMX 16 mcg", "V950 0.5 mcg/IMX 47 mcg", "V950 0.5 mcg/IMX 94 mcg", "V950 5 mcg/IMX 0 mcg", "V950 5 mcg/IMX 16 mcg", "V950 5 mcg/IMX 47 mcg", "V950 50 mcg/IMX 0 mcg", "V950 50 mcg/IMX 16 mcg", "Total"], ["Description", "Participants receive Placebo to V950/IMX 0 mcg", "Participants receive Placebo to V950/IMX 16 mcg", "Participants receive V950 0.5 mcg/IMX 0 mcg", "Participants receive V950 0.5 mcg/IMX 16 mcg", "Participants receive V950 0.5 mcg/IMX 47 mcg", "Participants receive V950 0.5 mcg/IMX 94 mcg", "Participants receive V950 5 mcg/IMX 0 mcg", "Participants receive V950 5 mcg/IMX 16 mcg", "Participants receive V950 5 mcg/IMX 47 mcg", "Participants receive V950 50 mcg/IMX 0 mcg", "Participants receive V950 50 mcg/IMX 16 mcg", "Total of all reporting groups"]], "pageTitle": "A Study of V950 in People With Alzheimer Disease (V950-001 AM7) - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00464334?term=V950", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 6, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981921.1/warc/CC-MAIN-20150728002301-00190-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 856767471, "recordOffset": 856757237, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants were recruited from 51 sites in Europe, South America and the United States. The primary treatment period was from June 2007 to August 2010, with follow up through January 2012. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Biological: V950 Biological: ISCOMATRIX\u2122 Biological: Placebo to V950 Interventions: Alzheimer Disease Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Diagnostic Study Design: Interventional", "textAfterTable": "\u00a0 \u00a0 Placebo to V950/IMX 0 mcg \u00a0 \u00a0 Placebo to V950/IMX 16 mcg \u00a0 \u00a0 V950 0.5 mcg/IMX 0 mcg \u00a0 \u00a0 V950 0.5 mcg/IMX 16 mcg \u00a0 \u00a0 V950 0.5 mcg/IMX 47 mcg \u00a0 \u00a0 V950 0.5 mcg/IMX 94 mcg \u00a0 \u00a0 V950 5 mcg/IMX 0 mcg \u00a0 \u00a0 V950 5 mcg/IMX 16 mcg \u00a0 \u00a0 V950 5 mcg/IMX 47 mcg \u00a0 \u00a0 V950 50 mcg/IMX 0 mcg \u00a0 \u00a0 V950 50 mcg/IMX 16 mcg \u00a0 STARTED \u00a0 \u00a0 5 \u00a0 \u00a0 13 \u00a0 \u00a0 8 \u00a0 \u00a0 8 \u00a0 \u00a0 7 \u00a0 \u00a0 7 \u00a0 \u00a0 9 \u00a0 \u00a0 8 \u00a0 \u00a0 8 \u00a0 \u00a0 5 \u00a0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}